Skip to main content
BIOTRON LIMITED logo

BIOTRON LIMITED — Investor Relations & Filings

Ticker · BIT ISIN · AU000000BIT4 ASX Professional, scientific and technical activities
Open in API
Filings indexed 766 across all filing types
Latest filing 2010-02-25 Interim / Quarterly Rep…
Country AU Australia
Listing ASX BIT

About BIOTRON LIMITED

https://www.biotron.com.au

Biotron Limited is a clinical-stage company focused on the development of novel small molecule antiviral therapeutics. The company utilizes its proprietary ViroPore technology platform to design and develop drugs that target viroporins—a class of proteins found in a wide range of viruses that play critical roles in viral replication and the evasion of host immune responses. Biotron's primary clinical program centers on BIT225, a first-in-class inhibitor targeting the HIV-1 Vpu protein and the Hepatitis C virus p7 protein. The company aims to address unmet medical needs by developing treatments that can potentially eradicate viral reservoirs and improve patient outcomes. In addition to HIV and HCV, Biotron is exploring the application of its antiviral platform against other significant viral pathogens, including SARS-CoV-2, leveraging its expertise in ion channel-targeting chemistry to disrupt the viral life cycle.

Recent filings

Filing Released Lang Actions
Half Yearly Report and Accounts 18 pages ?Kb
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM FINANCIAL REPORT FOR THE HALF YEAR ENDED 31 DECEMBER 2009' and includes detailed financial statements such as the Directors' Report, Interim Statement of Comprehensive Income, Balance Sheet, Cash Flows, and Notes. It references the half year period ending 31 December 2009 and includes substantive financial data and analysis. The presence of an auditor's review report further confirms this is a formal interim financial report. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2010
2010-02-25 English
Allotment and Top 20 securityholders - Options 2 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is a letter dated 5 February 2010 from Biotron Limited to ASX Limited regarding the allotment and distribution of new options. It details the completion of the allotment of 114,537,315 new options under an entitlement issue offer document dated 10 December 2009. The letter includes a list of the top 20 security holders of these new options and a distribution schedule. There is no financial statement, earnings data, or management discussion. The document is an announcement about a capital raising event involving new option allotment and distribution, which fits the category of Capital/Financing Update (CAP). The document length is short (2760 characters), but it contains substantive information about the allotment and distribution, not just a notice of report publication or certification. Therefore, the correct classification is CAP with high confidence.
2010-02-04 English
Appendix 4C - quarterly 5 pages ?Kb
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed financial data including consolidated statement of cash flows, cash reconciliation, and financing activities for a quarter ended 31 December 2009. It includes actual financial figures and explanations, consistent with a quarterly financial report. The document is over 7,000 characters, indicating it is a full report rather than a brief announcement. The presence of quarterly financial data and cash flow statements aligns with the definition of an Interim / Quarterly Report (IR). There is no indication that this is an announcement or certification only, nor is it a full annual report or other filing type. Therefore, the correct classification is IR (Interim / Quarterly Report). Q2 2009
2010-01-26 English
Change of Director`s Interest Notices 5 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references Listing Rule 3.19A. It details changes in securities holdings by directors Michael J. Hoy and Peter G. Scott, including the number of shares and options acquired or disposed, dates of changes, and nature of changes. The document is a formal notification to the ASX about directors' personal share transactions. It does not contain financial statements, management discussion, or other report content. This matches the definition of Director's Dealing filings, which report personal share transactions by company directors and executives (insider trades). The document length (6878 characters) is consistent with a detailed director dealing notice, not a full financial report or announcement of a report publication. Therefore, the correct classification is DIRS.
2010-01-21 English
Entitlement Issue 23% Oversubscribed 1 page ?Kb
Capital/Financing Update Classification · 95% confidence The document is a short announcement (917 characters) from the company secretary to the ASX regarding the outcome of an entitlement issue, specifically stating that the issue was oversubscribed by 23%. It references a previous ASX announcement dated 10 December 2009 but does not contain financial statements or detailed financial analysis. The content is about a capital raising event (entitlement issue) and its subscription status, which fits the category of Capital/Financing Update (CAP). The document is not a full report, nor is it a regulatory filing or announcement of a report publication. Therefore, the appropriate classification is CAP with high confidence.
2010-01-14 English
Breakthrough HIV Treatment Progresses 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a press release from Biotron Limited dated 17 December 2009, announcing progress on their HIV treatment drug BIT225. It discusses study results presented at an international conference and mentions publication of a scientific manuscript. The content focuses on scientific and clinical progress rather than financial results, regulatory filings, or shareholder information. The document is relatively short (4224 characters) and serves as a news announcement rather than a formal report or regulatory filing. There is no indication of financial data, management changes, voting results, or other formal corporate filings. Therefore, it best fits the category of a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2009-12-16 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.